The retailer’s new logo and brand system is a welcome, if familiar, update. The 255 million customers who visit Walmart each ...

One in eight adults in the U.S. has taken Ozempic or another type of GLP-1 drug, surveys show — and now a major new study has revealed a long list of benefits and some little-known risks.

Research shows that GLP-1 receptor agonists like Ozempic can help you drop weight, manage diabetes, and even potentially lower the risk of opioid overdoses. But now, a new study finds that taking ...

Mounjaro vs. Ozempic: Which Is Better for Weight Loss? This article was reviewed by Craig Primack, MD, FACP, FAAP, FOMA. In one corner, we’ve got Mounjaro, and in the other, Ozempic. They’re ...

You may take Ozempic or another drug to control your diabetes or lose weight, but these so-called GLP-1s also have a host of other effects ‒ some good and some not so good. A new study ...

From heart and kidney health to addiction reduction, GLP-1 drugs like Ozempic and Mounjaro may help with more than just weight loss Steve Christo/Corbis/Corbis/Getty ...

A new trend gaining popularity among people trying to lose weight is microdosing the diabetes medication Ozempic. With approximately 70% of American adults meeting the criteria for being obese or ...

Few drugs have captured public attention like Ozempic; many of us have even taken it. The type 2 diabetes medication, generically known as semaglutide, has received unprecedented attention in the ...

The move could mean savings for consumers. Weight loss drugs Ozempic and Wegovy have been added to the list of medications Medicare will be able to negotiate directly with drug manufacturers ...

Most people know that GLP-1 receptor agonist medications like Ozempic and Wegovy can cause relatively minor side effects like nausea and diarrhea. But new research confirms that more serious ...

In a ginormous new study, researchers have begun mapping the manifold health benefits of drugs like Ozempic and Wegovy beyond weight loss. Published in the journal Nature Medicine, this new study ...